疑似重度创伤性脑损伤院前诱导药物的比较:依托咪酯与氯胺酮
该研究基于BRAIN-PROTECT前瞻性队列的回顾性分析,纳入1457例疑似重度创伤性脑损伤并接受院前气道管理的患者,比较依托咪酯与S(+)-氯胺酮诱导对30天死亡率的影响。未调整分析显示两组死亡率分别为32.9%和33.8%(P=0.716),多变量logistic回归和逆概率加权分析均未发现显著关联,亚组分析结果一致。结论提示院前诱导药物选择可能不影响该人群的30天死亡率。
要点
- 依托咪酯与S(+)-氯胺酮诱导的30天死亡率无显著差异。
- 多变量校正后OR为1.08(95%CI 0.67-1.73),风险差0.017。
- 确诊和孤立性颅脑损伤亚组结果与总体一致。
核心结论
- 疑似重度创伤性脑损伤患者院前使用依托咪酯或S(+)-氯胺酮诱导插管与30天死亡率无显著关联。
研究设计与样本
- 基于BRAIN-PROTECT前瞻性队列的回顾性分析,纳入1457例疑似重度创伤性脑损伤并接受院前气道管理的患者。
主要发现
- 未调整分析中依托咪酯组30天死亡率为32.9%,S(+)-氯胺酮组为33.8%(P=0.716)。
- 多变量校正后OR为1.08(95%CI 0.67-1.73,P=0.765),风险差0.017(95%CI -0.051至0.084,P=0.686)。
- 确诊创伤性脑损伤和孤立性创伤性脑损伤亚组分析均未发现显著差异。
临床怎么用
- 在院前疑似重度创伤性脑损伤患者中,选择依托咪酯或S(+)-氯胺酮诱导插管对30天死亡率影响相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe traumatic brain injury is a leading cause of morbidity and mortality among young people around the world. Prehospital care focuses on the prevention and treatment of secondary brain injury and commonly includes tracheal intubation after induction of general anesthesia. The choice of induction agent in this setting is controversial. This study therefore investigated the association between the chosen induction medication etomidate versus S(+)-ketamine and the 30-day mortality in patients with severe traumatic brain injury who received prehospital airway management in the Netherlands. METHODS: This study is a retrospective analysis of the prospectively collected observational data of the Brain Injury: Prehospital Registry of Outcomes, Treatments and Epidemiology of Cerebral Trauma (BRAIN-PROTECT) cohort study. Patients with suspected severe traumatic brain injury who were transported to a participating trauma center and who received etomidate or S(+)-ketamine for prehospital induction of anesthesia for advanced airway management were included. Statistical analyses were performed with multivariable logistic regression and inverse probability of treatment weighting analysis. RESULTS: In total, 1,457 patients were eligible for analysis. No significant association between the administered induction medication and 30-day mortality was observed in unadjusted analyses (32.9% mortality for etomidate versus 33.8% mortality for S(+)-ketamine; P = 0.716; odds ratio, 1.04; 95% CI, 0.83 to 1.32; P = 0.711), as well as after adjustment for potential confounders (odds ratio, 1.08; 95% CI, 0.67 to 1.73; P = 0.765; and risk difference 0.017; 95% CI, -0.051 to 0.084; P = 0.686). Likewise, in planned subgroup analyses for patients with confirmed traumatic brain injury and patients with isolated traumatic brain injury, no significant differences were found. Consistent results were found after multiple imputations of missing data. CONCLUSIONS: The analysis found no evidence for an association between the use of etomidate or S(+)-ketamine as an anesthetic agent for intubation in patients with traumatic brain injury and mortality after 30 days in the prehospital setting, suggesting that the choice of induction agent may not influence the patient mortality rate in this population.
引用
- Mansvelder FJ, Bossers SM, Loer SA, et al. Etomidate versus Ketamine as Prehospital Induction Agent in Patients with Suspected Severe Traumatic Brain Injury. Anesthesiology. 2024. PMID: 38190220. doi:10.1097/ALN.0000000000004894
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。